Pediatric Patients
-
VTAMA® Cream Shows Early, Consistent Response in Children 2+ with Atopic Dermatitis
Organon presented data at ACAAI 2025 showing VTAMA cream’s efficacy in children (2-17) with atopic dermatitis (AD). A sub-analysis of Phase 3 trials (ADORING 1 & 2) revealed early and clinically meaningful improvements in skin clearance (vIGA-AD, EASI-75), patient-reported outcomes (POEM), and itch (PP-NRS) at week 8, regardless of comorbidities like asthma or allergies. This largest pediatric VTAMA data set supports its use as a treatment option, demonstrating a favorable safety and efficacy profile.
